INOVIO Interim Results of an Open-Label Phase 2 Trial of VGX-3...
PLYMOUTH MEETING, Pennsylvania, March 31, 2020 /PRNewswire-Asianet/ -- - VGX-3100 DNA medicine reduced qualifying high-risk HPV 16/18-associated precancerous vulvar lesion area in 80% of patients (by 60% on average); completely curing vulvar dysplasia with no virus detectable in 20% of patients- Data to be presen...
Authors: LATEST ASIANET NEWS RELEASES